Y 90 CHIMERIC T84 66 ANTI CEA ANTIBODY IN ADVANCE CEA PRODUCING MALIG

医师摘要：该试验将确定最大耐受剂量、相关毒性并评估腹膜内施用Y-90嵌合T84.66用于患有腹部癌病的患者的可行性。该试验还将评价辐射剂量测定、抗体生物分布和清除，并将开始评价其抗肿瘤作用。医师资格总结：癌胚抗原在肿瘤组织学诊断中的应用产生（癌胚抗原）的肿瘤;大多数癌症局限于腹膜腔，对既往常规治疗无反应;必须患有可测量或可评价的疾病;既往未接受过丝裂霉素C或亚硝基脲化疗;既往未接受过腹部或盆腔放射治疗或超过50%骨髓的放射治疗;肝脏受累超过25%的患者不合格;允许既往免疫治疗或化疗;年龄大于或等于18岁;必须达到或超过Karnofsky体能状态60%（患者偶尔需要帮助，但能够照顾自己的大部分需求）。

Physician Abstract: This trial will determine the maximum tolerated dose, the associated toxicities and evaluate the feasibility of delivering intraperitoneally administered Y-90 chimeric T84.66 for patients with abdominal carcinomatosis. This trial will also evaluate radiation dosimetry, antibody biodistribution and clearance and will begin to evaluate its anti-tumor effects. Physician Eligibility Summary: Histological diagnosis of cancer with CEA (Carcinoembryonic Antigen) producing tumors; Cancer of which the majority is confined to the peritoneal cavity and unresponsive to previous conventional treatment; Must have measurable or evaluable disease; No prior chemotherapy with Mitomycin-C or Nitrosureas; No prior abdomen or pelvic radiation therapy or radiation therapy to greater than 50% of bone marrow; Patients with greater than 25% liver involvement are ineligible; Prior immunotherapy or chemotherapy allowed; Age greater than or equal to 18 years; Must meet or exceed a Karnofsky Performance Status of 60% (Patient requires occasional assistance but is able to care for most of their own needs).